ADX10059: Additional Phase IIa data

A French Phase IIa trial in 24 patients with GERD that showed 250 mg oral ADX10059 reduced the number of symptomatic episodes vs. placebo (1.9 vs. 7, p=0.031). The duration of symptomatic episodes als...